These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antibacterial activity of sparfloxacin against experimental renal infections in mice. Georgopoulos A; Feistauer SM; Graninger W; Pfleger S; Georgopoulos M Antimicrob Agents Chemother; 1992 Feb; 36(2):505-7. PubMed ID: 1318685 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Meinen JB; McClure JT; Rosin E Am J Vet Res; 1995 Sep; 56(9):1219-24. PubMed ID: 7486402 [TBL] [Abstract][Full Text] [Related]
5. Initial clinical experience with clinafloxacin in the treatment of serious infections. Tack KJ; McGuire NM; Eiseman IA Drugs; 1995; 49 Suppl 2():488-91. PubMed ID: 8549411 [No Abstract] [Full Text] [Related]
8. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates. Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024 [TBL] [Abstract][Full Text] [Related]
9. Sparfloxacin therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Maserati R; Cagni AE; Segú C Chemotherapy; 1996; 42(2):133-9. PubMed ID: 8697888 [TBL] [Abstract][Full Text] [Related]
10. Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies. Cohen MA; Huband MD; Yoder SL; Gage JW; Roland GE J Antimicrob Chemother; 1998 Jun; 41(6):605-14. PubMed ID: 9687098 [TBL] [Abstract][Full Text] [Related]
11. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140 [TBL] [Abstract][Full Text] [Related]
12. Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer. Velpandian T; Gupta SK; Gupta YK; Agarwal HC; Biswas NR J Ocul Pharmacol Ther; 1999 Dec; 15(6):505-11. PubMed ID: 10609773 [TBL] [Abstract][Full Text] [Related]
13. A critical review of the fluoroquinolones: focus on respiratory infections. Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ Drugs; 2002; 62(1):13-59. PubMed ID: 11790155 [TBL] [Abstract][Full Text] [Related]
14. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853 [TBL] [Abstract][Full Text] [Related]
15. Clinafloxacin (CL 960) is superior to standard therapeutics in the treatment of murine listeriosis and salmonellosis. Nichterlein T; Bornitz F; Kretschmar M; Hof H Zentralbl Bakteriol; 1997 Oct; 286(3):401-12. PubMed ID: 9361386 [TBL] [Abstract][Full Text] [Related]
16. In vitro investigation of the intraphagocytic bioactivities of ciprofloxacin and the new fluoroquinolone agents, clinafloxacin (CI-960) and PD 131628. Anderson R; Jooné GK Chemotherapy; 1993; 39(6):424-31. PubMed ID: 8222871 [TBL] [Abstract][Full Text] [Related]
17. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci]. Wallrauch C; Voss A; Milatovic D; Braveny I Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580 [TBL] [Abstract][Full Text] [Related]
18. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. Aubert G; Pozzetto B; Dorche G J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371 [TBL] [Abstract][Full Text] [Related]